UroGen Pharma Reports $109.8M Revenue, Widened $(3.19) Net Loss in 2025 10-K
Summary
UroGen Pharma reported its 2025 fiscal year financial results from its 10-K filing, revealing $109.8 million in revenue and a net loss of $(3.19) per share. While revenue increased by $19.4 million year-over-year, driven by the launch of Zusduri and growth in Jelmyto sales, the company's net loss widened to $153.5 million from $126.9 million in 2024. This increase in loss is primarily attributed to higher operating expenses, including R&D and commercial spending, as well as increased financing costs. This financial update provides a comprehensive view of the company's performance following recent positive news regarding its Phase 3 ENVISION trial and a $250 million amended loan agreement. Traders will be assessing the company's path to profitability amidst its ongoing commercial scale-up and pipeline investments.
At the time of this announcement, URGN was trading at $22.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $3.42 to $30.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Unknown.